Literature DB >> 29707266

Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care?

Anna W Chalmers1, Shiven B Patel1, Wallace Akerley1.   

Abstract

Entities:  

Year:  2018        PMID： 29707266      PMCID： PMC5906257          DOI： 10.21037/jtd.2018.01.160

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  15 in total

1.  Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.

Authors:  Narek Shaverdian; Aaron E Lisberg; Krikor Bornazyan; Darlene Veruttipong; Jonathan W Goldman; Silvia C Formenti; Edward B Garon; Percy Lee
Journal:  Lancet Oncol       Date:  2017-05-24       Impact factor: 41.316

Review 2.  Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

Authors:  Anne Aupérin; Cecile Le Péchoux; Estelle Rolland; Walter J Curran; Kiyoyuki Furuse; Pierre Fournel; Jose Belderbos; Gerald Clamon; Hakki Cuneyt Ulutin; Rebecca Paulus; Takeharu Yamanaka; Marie-Cecile Bozonnat; Apollonia Uitterhoeve; Xiaofei Wang; Lesley Stewart; Rodrigo Arriagada; Sarah Burdett; Jean-Pierre Pignon
Journal:  J Clin Oncol       Date:  2010-03-29       Impact factor: 44.544

3.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

5.  Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

Authors:  Chee Khoon Lee; Johnathan Man; Sally Lord; Matthew Links; Val Gebski; Tony Mok; James Chih-Hsin Yang
Journal:  J Thorac Oncol       Date:  2016-10-17       Impact factor: 15.609

6.  Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

Authors:  Walter J Curran; Rebecca Paulus; Corey J Langer; Ritsuko Komaki; Jin S Lee; Stephen Hauser; Benjamin Movsas; Todd Wasserman; Seth A Rosenthal; Elizabeth Gore; Mitchell Machtay; William Sause; James D Cox
Journal:  J Natl Cancer Inst       Date:  2011-09-08       Impact factor: 13.506

Review 7.  Concurrent chemoradiotherapy in non-small cell lung cancer.

Authors:  Noelle O'Rourke; Marta Roqué I Figuls; Nuria Farré Bernadó; Fergus Macbeth
Journal:  Cochrane Database Syst Rev       Date:  2010-06-16

8.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.

Authors:  Jeffrey D Bradley; Rebecca Paulus; Ritsuko Komaki; Gregory Masters; George Blumenschein; Steven Schild; Jeffrey Bogart; Chen Hu; Kenneth Forster; Anthony Magliocco; Vivek Kavadi; Yolanda I Garces; Samir Narayan; Puneeth Iyengar; Cliff Robinson; Raymond B Wynn; Christopher Koprowski; Joanne Meng; Jonathan Beitler; Rakesh Gaur; Walter Curran; Hak Choy
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

9.  Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04.

Authors:  Jin Seok Ahn; Yong Chan Ahn; Joo-Hang Kim; Chang Geol Lee; Eun Kyung Cho; Kyu Chan Lee; Ming Chen; Dong-Wan Kim; Hoon-Kyo Kim; Young Joo Min; Jin-Hyoung Kang; Jin-Hyuck Choi; Sang-We Kim; Guangying Zhu; Yi-Long Wu; Sung Rok Kim; Kyung Hee Lee; Hong Suk Song; Yoon-La Choi; Jong-Mu Sun; Sin-Ho Jung; Myung-Ju Ahn; Keunchil Park
Journal:  J Clin Oncol       Date:  2015-07-06       Impact factor: 44.544

10.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.